Ascendis Pharma A-S

Yahoo Finance • 2 days ago

European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading

European equities traded in the US as American depositary receipts were trending lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 days ago

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon CNP (navepegritide... Full story

Yahoo Finance • 11 days ago

European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking slightly higher Tue PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual meeting of the America... Full story

Yahoo Finance • last month

European Equities Traded in the US as American Depositary Receipts Start Week Sharply Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were sharply lower late Tuesday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Technical Strength and High-Growth Momentum

In the world of growth investing, combining technical strength with fundamental momentum often yields strong opportunities. One approach gaining traction with traders is the integration of Mark Minervini’s Trend Template, a systematic meth... Full story

Yahoo Finance • last month

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

COPENHAGEN, Denmark, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts

Ascendis Pharma reported its Q2 2025 earnings, revealing a significant earnings per share (EPS) beat with an actual EPS of -0.82 compared to the forecast of -1.27, marking a surprise of 35.43%. Revenue also surpassed expectations, reaching... Full story

Yahoo Finance • 2 months ago

CGGR's Underlying Holdings Imply 10% Gain Potential

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 2 months ago

Stocks Climb Before the Open on Chip Tariff Relief and Ukraine Truce Hopes

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.81%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are up +0.78% this morning as... Full story

Yahoo Finance • 2 months ago

European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Wednesd PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results

Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $200.00 price target on Ascendis Pharma (NASDAQ:ASND) ahead of the company’s second-quarter earnings report scheduled for Thursday, August 7. The stock, which has su... Full story

Yahoo Finance • 2 months ago

Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of... Full story

Yahoo Finance • 2 months ago

Ascendis wins FDA approval for growth hormone deficiency treatment

[FDA approved red rubber stamp] tang90246 * The U.S. FDA has approved Ascendis Pharma's (ASND [https://seekingalpha.com/symbol/ASND]) Skytrofa (lonapegsomatropin) as a once-weekly treatment for adults with growth hormone deficiency (GHD... Full story

Yahoo Finance • 3 months ago

Ascendis Pharma reports positive results from hypothyroid trial

[Human Body Glands Thyroid Gland Anatomy] magicmine/iStock via Getty Images * Ascendis Pharma A/S (ASND [https://seekingalpha.com/symbol/ASND]) shared results from week 156 of its late-stage trial, showing that long-term use of TransCon... Full story

Yahoo Finance • 3 months ago

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with TransCon PTH (palopegteriparatide) con... Full story

Yahoo Finance • 3 months ago

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr.... Full story

Yahoo Finance • 3 months ago

Ascendis Pharma's SWOT analysis: promising pipeline propels stock potential

Ascendis Pharma (NASDAQ:ASND) A/S, a biopharmaceutical company focused on developing innovative therapies for rare endocrine disorders, has garnered significant attention from analysts due to its strong product launches and promising pipel... Full story

Yahoo Finance • 4 months ago

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Ascendis Pharma price target raised to $224 from $215 at Oppenheimer

Oppenheimer raised the firm’s price target on Ascendis Pharma (ASND) to $224 from $215 and keeps an Outperform rating on the shares. The firm’s commissioned survey of 20 U.S. hypoparathyroid-treating endocrinologists indicates robust early... Full story